International Clinical Trials in Gastroenterology

Algeria

• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Alger; Research Site:
  
  

Argentina

• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Bahia Blanca; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Buenos Aires ; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Córdoba; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  La Plata; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Rosario; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  San Miguel De Tucuman; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Santa Fe; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Buenos Aires ; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Buenos Aires ; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Rosario; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Rosario; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  San Martín; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Villa Domínico; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Buenos Aires ; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Santa Fe; Research Site:
  
  

Australia

• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Fitzroy; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Malvern; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Wollongong; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Darlinghurst; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Fremantle; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Heidelberg; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Kingswood; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Port Macquarie; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  St. Leonards; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Waratah; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Waratah; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Wodonga; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
  Fitzroy; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Fitzroy; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Malvern; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Port Macquarie; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  St. Leonards; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Bendigo; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Brisbane; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Fitzroy; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Port Macquarie; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  St. Leonards; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Wodonga; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Adelaide; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Melbourne; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Perth; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Port Macquarie; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Sydney; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Wollongong; Research Site:
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Fremantle; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Parkville, VIC; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Multi-Center, Open-Label Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
  Box Hill; UCB Clinical Trial Call Center
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Adelaide; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Heidelberg; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Melbourne; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Sydney; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Adelaide; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Brisbane; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Melbourne; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Perth; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Melbourne; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  St. Leonards; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Sydney; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Adelaide; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Ballarat; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Brisbane; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Canberra; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Frankston; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Liverpool; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  St. Leonards; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Sydney; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Adelaide; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Heidelberg; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Melbourne; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  St. Leonards; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Sydney; Research Site:
  
  

Australlia

• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Box Hill; UCB Clinical Trial Call Center
  
  

Austria

• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Graz; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Wien; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Graz; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Innsbruck; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Klagenfurt; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Leoben; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Linz; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Salzburg; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Vöcklabruck; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Wien; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Innsbruck; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Linz; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Salzburg; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Wien; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Bludesch; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Dornbirn; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Graz; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Hall In Tirol; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Innsbruck; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Knittelfeld; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Krems; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Leoben; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Linz; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Ried-Innkreis; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Salzburg; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  St Pölten; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  St Veit an der Glan; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Villach; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Waidhofen A D Thaya; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
  Wien; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Wels; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Wien; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Hall In Tirol; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Innsbruck; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Klagenfurt; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Oberwart; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  St Pölten; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Wien; Research Site:
  
  
• Gastric Cancer: A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
  Wien; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Salzburg; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Wien; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Graz; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Salzburg; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Wien; Research Site:
  
  

Bangladesh

• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Dhaka; Research Site:
  
  

Belgium

• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Bruxelles; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Gent; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Leuven; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Antwerpen; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Arlon; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Brasschaat; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Bruxelles; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Charleroi; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Edegem; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Genk; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Gent; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Haine-Saint-Paul; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Kortrijk; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Leuven; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Libramont; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Liege; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Mont-Godinne; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Wilrijk; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Bruxelles; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Bruxelles; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Gent; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Kortrijk; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Mont-Godinne; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Bruxelles; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Charleroi; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Gent; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Kortrijk; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Leuven; Research Site:
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Bonheiden; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Brussels; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Gent; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Leuven; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Liege; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Roeselare; UCB Clinical Trial Call Center
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Leuven; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Leuven; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Antwerpen; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Bruxelles; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Gent; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Leuven; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Liege; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Antwerpen; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Bruxelles; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Leuven; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Wilrijk; Research Site:
  
  

Brazil

• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Porto Alegre; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Rio De Janeiro; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Sao Paulo; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Sorocaba; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Belo Horizonte; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Brasilia; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Campinas; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Caxias do Sul; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Curitiba; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Fortaleza; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Ijuí; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Porto Alegre; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Recife; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Ribeirão Preto; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Rio De Janeiro; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Salvador; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Sao Paulo; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Belo Horizonte; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Brasilia; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Campinas; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Caxias do Sul; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Curitiba; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Fortaleza; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Ijuí; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Porto Alegre; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Recife; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Ribeirão Preto; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Rio De Janeiro; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Salvador; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum.
  Sao Paulo; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
  Salvador; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
  Sao Paulo; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Previously Untreated Metastatic Colorectal Cancer.
  Sorocaba; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Jaú; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Rio De Janeiro; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Sao Paulo; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Porto Alegre; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Rio De Janeiro; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Sao Paulo; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Sorocaba; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Belo Horizonte; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Jaú; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Sao Paulo; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Barretos; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Fortaleza; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Goiania; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Jaú; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Porto Alegre; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Rio De Janeiro; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Salvador; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Sao Paulo; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Sorocaba; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Barretos; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Curitiba; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Florianopolis; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Fortaleza; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Porto Alegre; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Sao Paulo; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Patients With Advanced or Metastatic Gastric Cancer
  Sorocaba; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Barretos; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Rio De Janeiro; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Sao Paulo; Research Site:
  
  
• Gastric Cancer: ToGA study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric Cancer
  Sorocaba; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Belo Horizonte; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Curitiba - Pr; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Ijuí; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Jaú; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Porto Alegre; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Porto Alegre - Rs; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Porto Alegre Rs; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Salvador; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Sao Paulo; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Belo Horizonte; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Ijuí; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Salvador; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Santo Andre; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Sao Paulo; Research Site:
  
  

Bulgaria

• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Plovdiv; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Sofia; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Stara Zagora; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Varna; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Sofia; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Plovdiv; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Sofia; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Stara Zagora; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in the Adjuvant Treatment of Patients With Resected Colon Cancer
  Blagoevgrad; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in the Adjuvant Treatment of Patients With Resected Colon Cancer
  Ruse; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in the Adjuvant Treatment of Patients With Resected Colon Cancer
  Shumen; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in the Adjuvant Treatment of Patients With Resected Colon Cancer
  Sofia; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in the Adjuvant Treatment of Patients With Resected Colon Cancer
  Veliko Tarnovo; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Gabrovo; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Pleven; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Plovdiv; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Sofia; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Varna; Research Site:
  
  
• Pancreatic Cancer: A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer
  Vratza; Research Site:
  
  

Canada

• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Calgary, AR; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Edmonton, AB; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Kelowna, BC; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Montreal, QC; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Toronto, ON; Research Site
  
  
• Celiac Disease: A Dose Ranging Study to Determine the Safety, Tolerance, and Efficacy of an Investigational Drug AT-1001 in Celiac Disease Subjects during a Gluten Challenge
  Winnipeg, MB; Research Site
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Brampton, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Edmonton, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Greenfield Park, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Kelowna, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Levis, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  London, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Mississauga, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Moncton, NB; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Montreal, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Oshawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Ottawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Quebec City, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Surrey, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Sydney, NS; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Thunder Bay, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Toronto, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Vancouver, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Victoria, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Weston, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Winnipeg, MB; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Barrie, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Brampton, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Calgary, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Edmonton, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Greenfield Park, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Halifax, NS; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Kelowna, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Kingston, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Kitchener, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Laval, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Levis, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Mississauga, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Moncton, NB; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Montreal, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  New Westminster, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Newmarket, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Oshawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Ottawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Quebec City, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Regina, SK; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Saskatoon, SK; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Sault Ste Marie, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Scarborough, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  St John'S; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  St-Jerome, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Sudbury, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Surrey, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Sydney, NS; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Toronto, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Toronto, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Vancouver, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Victoria, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Weston, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Windsor, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Winnipeg, MB; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Calgary, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Halifax, NS; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Montreal, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Ottawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Toronto, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) in Elderly Patients With Metastatic Colorectal Cancer.
  Vancouver, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
  Brampton, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
  Hamilton, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With XELOX or FOLFOX-4 in Patients With Metastatic Colorectal Cancer.
  Toronto, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Calgary, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Edmonton, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Halifax, NS; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Hamilton, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Kelowna, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Levis, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Mississauga, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Montreal, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  North Vancouver, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Oshawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Ottawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Quebec City, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  St. Catharines, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Surrey, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Toronto, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Vancouver, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Victoria, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Weston, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Winnipeg, MB; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Calgary, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Kelowna, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Montreal, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Ottawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Saskatoon, SK; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
  Winnipeg, MB; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
  Hamilton, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
  Ottawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Combination With Oxaliplatin in Patients With Metastatic Colorectal Cancer.
  Toronto, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Edmonton, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Halifax, NS; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Laval, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Levis, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  London, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Montreal, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Oshawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Ottawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Quebec City, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Regina, SK; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  St John'S; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  St. Catharines, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Thunder Bay, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Toronto, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer
  Weston, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Calgary, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Edmonton, AB; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Halifax, NS; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Hamilton, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Kelowna, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Laval, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Levis, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  London, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Mississauga, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Montreal, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Oshawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Ottawa, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Quebec City, QC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  St John'S; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Surrey, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Toronto, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Victoria, BC; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Weston, ON; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Winnipeg, MB; Research Site:
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  Abbotsford, British Columbia; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  Calgary, Alberta; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  Edmonton, Alberta; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  London, Ontario; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  Saskatoon, Saskatchewan; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  Toronto, Ontario; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  Toronto, Ontario; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  Vancouver, British Columbia; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  Vancouver, British Columbia; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Corticosteroid Sparing Effect of Certolizumab
  Winnipeg, Manitoba; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
  Abbottsford, British Columbia; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
  Calgary; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
  Edmonton, Alberta; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
  London, Ontario; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
  Saskatoon, Saskatchewan; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
  Toronto, Ontario; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
  Toronto, Ontario; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
  Vancouver, British Columbia; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Extension Study to Evaluate Safety, Efficacy, and Corticosteroid Sparing Effect of Certolizumab in Patients With Crohn's Disease.
  Winnipeg, Manitoba; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Hamilton; UCB Clinical Trial Call Center
  
  
• Crohn's Disease: Multi-Center Double -Blind Randomized Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Response in Patients With Crohn's Disease
  Winnipeg; UCB Clinical Trial Call Center
  
  
• Crohn's Disease (Pediatric): Would you be interested in participating in a pediatric clinical research trial with treatment for Pediatric Crohn’s Disease?
  Ottawa, Ontario; Research Site
  
  
• Inflammatory Bowel Disease: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Edmonton, AB; Aberthart Centre #1
  
  
• Inflammatory Bowel Disease: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Halifax, NS; IWK Health Centre
  
  
• Inflammatory Bowel Disease: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Hamilton, ON; McMaster Children's Hospital
  
  
• Inflammatory Bowel Disease: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Toronto, ON; The Hospital for Sick Children
  
  
• Inflammatory Bowel Disease: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Vancouver, BC; B.C. Children's Hospital
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Edmonton, AB; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Mississauga, ON; Research Site:
  
  
• Pancreatic Cancer: A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer
  Toronto, ON; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Edmonton, AB; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Montreal, QC; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Ottawa, ON; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Quebec City, QC; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Toronto, ON; Research Site:
  
  
• Pancreatic Cancer: A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer
  Vancouver, BC; Research Site:
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Vancouver, British Columbia; Liver and Intestinal Research Centre
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Montreal, Quebec; Montreal General Hospital
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Montreal, Quebec; Hôpital Maisonneuve - Rosemont
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Saskatoon, SK; Medical Digestive
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Kingston, Ontario; Hotel Dieu Hospital - Kingston
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Quebec; CHAUQ - Hopital du St-Sacrement
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  London, Ontario; London Health Science Centre
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Hamilton, Ontario; McMaster University Health Sciences Center
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Victoria, British Columbia; PerCuro Clinical Research Ltd.
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Intravenously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Calgary, Alberta; University of Calgary
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Saskatoon, SK; Edwin Larkai Medical Professional Corporation
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Toronto, Ontario; Sunnybrook Health Sciences Centre
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Toronto, Ontario; Toronto Digestive Disease Associates, Inc.
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Winnipeg, MB; Health Sciences Centre
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Montreal, Quebec; Jewish General Hospital
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Montreal, Quebec; CHUM Hopital Saint-Luc
  
  
• Ulcerative Colitis: A Phase 2/3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Induction Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Ottawa, Ontario; Hassard, Philip MD
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Calgary, Alberta; University of Calgary
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Quebec; CHAUQ - Hopital du St-Sacrement
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Kingston, Ontario; Hotel Dieu Hospital - Kingston
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Saskatoon, SK; Medical Digestive
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Saskatoon, SK; Edwin Larkai Medical Professional Corporation
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Victoria, British Columbia; PerCuro Clinical Research Ltd.
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Toronto, Ontario; Toronto Digestive Disease Associates, Inc.
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Toronto, Ontario; Sunnybrook Health Sciences Centre
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Vancouver, British Columbia; Liver and Intestinal Research Centre
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  London, Ontario; London Health Science Centre
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Hamilton, Ontario; McMaster University Health Sciences Center
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Winnipeg, MB; Health Sciences Centre
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Montreal, Quebec; Hôpital Maisonneuve - Rosemont
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Montreal, Quebec; Montreal General Hospital
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Montreal, Quebec; CHUM Hopital Saint-Luc
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Montreal, Quebec; Jewish General Hospital
  
  
• Ulcerative Colitis: A Phase 3 Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Golimumab Maintenance Therapy, Administered Subcutaneously, in Subjects With Moderately to Severely Active Ulcerative Colitis
  Ottawa, Ontario; Hassard, Philip MD
  
  
• Ulcerative Colitis: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Edmonton, AB; Aberthart Centre #1
  
  
• Ulcerative Colitis: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Halifax, NS; IWK Health Centre
  
  
• Ulcerative Colitis: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Hamilton, ON; McMaster Children's Hospital
  
  
• Ulcerative Colitis: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Toronto, ON; The Hospital for Sick Children
  
  
• Ulcerative Colitis: Does your child have Ulcerative Colitis? You may want to look into our research study available for children with moderately to severely active Ulcerative Colitis (UC).
  Vancouver, BC; B.C. Children's Hospital
  
  

China

• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Beijing; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Guangzhou; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Hangzhou; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Hong Kong; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) Added to Various Chemotherapy Regimens in Patients With Colon Cancer
  Shanghai; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
  Beijing; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
  Chongqing; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
  Guangdong; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
  Guangzhou; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
  Nanjing; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
  Qingdao; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
  Shanghai; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
  Tianjin; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Chinese Patients With Metastatic Colorectal Cancer.
  Wuhan; Research Site:
  
  
• Colorectal Cancer: A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum
  Hong Kong; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Beijing; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Guangdong; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Guangzhou; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Hong Kong; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Jiangsu; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Jiangxi; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Shandong; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Shanghai; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Tianjin; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) as a First-Line Therapy in Patients With Metastatic Colorectal Cancer
  Wuhan; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Beijing; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Guangdong; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Hangzhou; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Hong Kong; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Jiangsu; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Jiangxi; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Shandong; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Shanghai; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Tianjin; Research Site:
  
  
• Colorectal Cancer: A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
  Wuhan; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Beijing; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Chongqing; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Guangzhou; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Hong Kong; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Shanghai; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Shenyang; Research Site:
  
  
• Gastric Cancer: A Study of Avastin (Bevacizumab) in Combination With Xeloda (Capecitabine) and Cisplatin in Patients With Advanced Gastric Cancer.
  Suzhou; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Combination Chemotherapy Versus Surgery Alone in Patients With Gastric Cancer
  Beijing; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Combination Chemotherapy Versus Surgery Alone in Patients With Gastric Cancer
  Fuzhou; Research Site:
  
  
• Gastric Cancer: A Study of Xeloda (Capecitabine) in Combination Chemotherapy Versus Surgery Alone in Patients With Gastric Cancer
  Guangzhou; Research Site:
  
  
• Gastric Cancer: